David Whitston
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Microtubule and mitosis dynamics, Pluripotent Stem Cells Research, Cancer-related Molecular Pathways, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Discovery of a Novel Class of Dimeric Smac Mimetics as Potent IAP Antagonists Resulting in a Clinical Candidate for the Treatment of Cancer (AZD5582)(2013)113 cited
- → Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases(2012)45 cited
- → Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent(2011)43 cited
- → Generation of stable PDX derived cell lines using conditional reprogramming(2017)39 cited
- → Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors(2018)28 cited
- → Abstract CT024: Durvalumab (D) + platinum-etoposide (EP) in 1L extensive-stage small-cell lung cancer (ES-SCLC): Exploratory analysis of SCLC molecular subtypes in CASPIAN(2022)25 cited
- → Discovery of 6-aryl-azabenzimidaoles that inhibit the TBK1/IKK-ε kinases(2014)16 cited
- → Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)(2017)4 cited
- → Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia(2024)3 cited
- → Abstract 641: Use of conditional reprogramming to develop and characterize cell cultures from patient-derived xenograft (PDX) models of human lung and ovarian cancer(2016)1 cited